|Table of Contents|

Pathological complete response rate and influencing factors of neoadjuvant chemotherapy for breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 03
Page:
472-476
Research Field:
Publishing date:

Info

Title:
Pathological complete response rate and influencing factors of neoadjuvant chemotherapy for breast cancer
Author(s):
GOU Qingxiang1; GAO Jinnan1; 2; WANG Jintao1
1.Shanxi Medical University,Shanxi Taiyuan 030001,China;2.Department of Breast Surgery,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences' Tongji Shanxi Hospital,Third Hospital of Shanxi Medical University,Shanxi Taiyuan 030032,China.
Keywords:
breast cancer; neoadjuvant chemotherapy; breast-conserving surgery; pathologic complete remission
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2024.03.014
Abstract:
Objective:To analyze related factors of pathologic complete remission(pCR) rate after neoadjuvant chemotherapy(NAC),and provided reference and basis for the application of NAC combined BCS for breast cancer（BC） patients.Methods：The subjects of this study were female stage Ⅱ-Ⅲ BC patients treated in the breast surgery Department of the Third Affiliated Hospital of Shanxi Medical University from January 2013 to December 2021.Demographic characteristics,clinicopathologic data and chemotherapy-related information were collected to observe the clinical and pathological changes of the primary tumor in order to evaluate the short-term efficacy of NAC.Results：A total of 260 subjects were included in the study.The BCS rate was 21.9%,and the pCR rate was 18.1%.The univariate analysis of pCR showed that lactation(P＜0.05),ER,PR,HER-2,Ki-67,molecular typing,targeted therapy,and treatment regimen were all correlated with breast pCR(P≤0.001).In the multivariate analysis,tumor molecular typing(OR=0.077,95%CI:0.022~0.262) was significantly associated with breast pCR.Conclusion：NAC can lead to tumor reduction and increase the rate of BCS and pCR rate.There were significant differences in pCR rates among different molecular subtypes,especially in triple negative breast cancer patients.Surgeons can select BC patients suitable for NAC and improve patients' quality of life.

References:

[1]ATASEVEN B,VON MINCKWITZ G.The impact of neoadjuvant treatment on surgical options and outcomes ［J］.Annals of Surgical Oncology,2016,23(10):3093-3099.
[2]郭燕,张丽娜,顾林.新辅助化疗联合保乳手术可行性研究 ［J］.肿瘤,2018,38(03):242-249. GUO Y,ZHANG LN,GU L.Feasibility of neoadjuvant chemotherapy combined with breast conserving surgery for breast cancer ［J］.Cancer,2018,38(03):242-249.
[3]GOLSHAN M,CIRRINCIONE CT,SIKOV WM,et al.Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer:surgical results of CALGB 40601(Alliance) ［J］.Breast Cancer Research and Treatment,2016,160(2):297-304.
[4]HARRY DB,ANDERSON S,ROY ES,et al.Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National surgical adjuvant breast and bowel project protocol B-27［J］.J Clin Oncol,2006,24(13):2019-2027.
[5]CRISCITIELLO C,AZIM HA,AGBOR-TARH D,et al.Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer:results from the NeoALTTO phase III trial ［J］.Annals of Oncology,2013,24(8):1980-1985.
[6]GOLSHAN M,LOIBL S,WONG SM,et al.Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer(vol 155,e195410,2020) ［J］.Jama Surgery,2021,156(5):503.
[7]CHANG YK,CO M,KWONG A.Conversion rate from mastectomy to breast conservation after neoadjuvant dual target therapy for HER2-positive breast cancer in the Asian population ［J］.Breast Cancer,2020,27(3):456-463.
[8]GRAHAM P,BRAR M,FOSTER T,et al.Neoadjuvant chemotherapy for breast cancer-is practice changing?A population-based review of current surgical trends ［J］.Annals of Surgical Oncology,2015,22:56-57.
[9]XU B,SHEN JG,ZHANG LW,et al.HER2 protein expression level is positively associated with the efficacy of neoadjuvant systemic therapy in HER2-positive breast cancer ［J］.Pathology Research and Practice,2022,234:5.
[10]LOIBL S,O' SHAUGHNESSY J,UNTCH M,et al.Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer(BrighTNess):a randomised,phase 3 trial ［J］.Lancet Oncology,2018,19(4):497-509.
[11]徐经涛,罗泽民.HER-2阳性乳腺癌新辅助治疗的研究进展 ［J］.临床医学研究与实践,2022,7(16):195-198. XU JT,LUO ZM.Research progress of neoadjuvant therapy for HER-2 positive breast cancer［J］.Clinical Research and Practice,2022,7(16):195-198.
[12]史文婷,肖秋梅,张相机,等.乳腺癌新辅助化疗疗效的影响因素研究 ［J］.中国医药科学,2020,10(16):130-133. SHI WT,XIAO QM,ZHANG XJ,et al.Study of factors influencing therapeutic efficacy of neoadjuvant chemotherapy for breast cancer［J］.China Medicine and Pharmacy,2020,10(16):130-133.
[13]何伟丽,练会招,翟贺宁,等.乳腺癌患者新辅助化疗效果 ［J］.中国老年学杂志,2022,42(07):1598-1601. HE WL,LIAN HZ,ZHAI HN,et al.Effect of neoadjuvant chemotherapy in patients with breast cancer ［J］.Chinese Journal of Gerontology,2022,42(07):1598-1601.
[14]WOO J,OH SJ,SONG JY,et al.Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer:a large,multicenter,observational study ［J］.Bmc Cancer,2021,21(1):11.
[15]MAN V CM,CHEUNG P SY.Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer ［J］.Hong Kong Medical Journal,2017,23(3):251-257.
[16]王健宇,张显玉,庞达.Luminal A型乳腺癌新辅助化疗疗效的影响因素分析 ［J］.实用肿瘤学杂志,2021,35(02):131-136. WANG JY,ZHANG XY,PANG D.Influencing factors of neoadjuvant chemotherapy for Luminal A type breast cancer ［J］.Practical Oncology Journal,2021,35(02):131-136.
[17]高国璇,张岩,张虹,等.乳腺癌新辅助治疗病理完全缓解影响因素及预后分析 ［J］.中国实用外科杂志,2016,36(11):1205-1210. GAO GX,ZHANG Y,ZHANG H,et al.Analysis of the predicted factors of pathological complete response(pCR) after neoadjuvant systemic therapy in primary breast cancer andthe prognostic value of pCR［J］.Chinese Journal of Practical Surgery,2016,36(11):1205-1210.
[18]TAN QX,QIN QH,YANG WP,et al.Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy ［J］.International Journal of Clinical and Experimental Pathology,2014,7(10):6862-6870.
[19]王伟,张伟杰,庄晓明,等.乳腺癌HER2低表达对新辅助化疗疗效影响的临床观察 ［J］.现代肿瘤医学,2023,31(19):3600-3604. WANG W,ZHANG WJ,ZHUANG XM,et al.Impact of HER2 low expression on neoadjuvant chemotherapy in breast cancer:A single-center,small-sample retrospective study［J］.Modern Oncology,2023,31(19):3600-3604.
[20]郑璐,汤铜,王芝涛,等.影响HER-2低表达乳腺癌新辅助化疗疗效及预后的相关因素分析 ［J］.现代肿瘤医学,2023,31(20):3784-3790. ZHENG L,TANG T,WANG ZT,et al.Analysis of factors affecting the efficacy and prognosis of neoadjuvant chemotherapy in patients with HER-2-low-positive breast cancer［J］.Modern Oncology,2023,31(20):3784-3790.
[21]曲天宇，葛一涵，赵毅.乳腺癌患者新辅助化疗后病理完全缓解的相关影响因素分析及列线图预测模型的构建 ［J］.现代肿瘤医学，2021,29(04):590-594. QU TY,GE YH,ZHAO Y.Related factors analysis on breast cancer patients' pathologic complete response after neoadjuvant therapy and establishment of a nomogram prediction model ［J］.Modern Oncology,2021,29(04):590-594.
[22]颜娇,叶入裴,杨琴,等.不同亚型乳腺癌新辅助化疗后Ki-67表达变化与乳腺癌疗效及预后的相关性 ［J］.诊断病理学杂志,2022,29(11):1001-1004. YAN J,YE RF,YANG Q,et al.Correlation between Ki-67 expression and breast cancer efficacy and prognosis after neoadjuvant chemotherapy in different subtypes of breast cancer［J］.Chinese Journal of Diagnostic Pathology,2022,29(11):1001-1004.
[23]SWISHER SK,VILA J,TUCKER SL,et al.Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy ［J］.Annals of Surgical Oncology,2016,23(3):749-756.
[24]CHOU HH,KUO WL,YU CC,et al.Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy ［J］.Biomedical Journal,2019,42(1):66-74.
[25]朱坤兵,徐灿,李晓霞,等.乳腺癌分子分型与新辅助化疗效果的关系 ［J］.中华乳腺病杂志(电子版),2016,10(03):166-169. ZHU KB,XU C,LI XX,et al.Correlation between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer patients［J］.Chinese Journal of Breast Disease(Electronic Version),2016,10(03):166-169.
[26]杨柳,张明坤,季福庆,等.HER-2阳性乳腺癌新辅助化疗疗效影响因素分析及相关预后模型的构建 ［J］.现代肿瘤医学,2023,31(11):2037-2041. YANG L,ZHANG MK,JI FQ,et al.The analysis of the factors affecting pathological complete response of HER-2 positive breast cancer patients after neoadjuvant chemotherapy and the construction of related model［J］.Modern Oncology,2023,31(11):2037-2041.

Memo

Memo:
山西省医学重点科技项目计划（编号：2022XM01）
Last Update: 2023-12-29